PDF icon Download PDF
Open Access
CC BY-NC-ND 4.0 · Journal of Diabetes and Endocrine Practice 2019; 02(01): 4-7
DOI: 10.4103/jdep.jdep_9_18
Original Article

Clinical study on the application of acupoint injection therapy with vitamin B1 in patients with diabetic peripheral neuropathy

Ran-Hui Kang
Department of Endocrinology and Metaboism, Pyongyang Medical College, Kim II Sung University, Pyongyang, DPR Korea
,
O Kwang-Chun
Department of Endocrinology and Metaboism, Pyongyang Medical College, Kim II Sung University, Pyongyang, DPR Korea
› Author Affiliations
› Further Information
Also available ateRef
  Permissions and Reprints
Preview

Context: Acupoint injection therapy with Vitamin B1is very effective in the management of diabetic peripheral neuropathy (DPN), and there are few adverse side effects. Aims: The overall purposes of our study are to determine the specific methods of acupoint injection therapy with Vitamin B1for patients with DPN and to demonstrate the effectiveness of this therapy for DPN patients. Settings and Design: The enrolled patients were divided into two groups – the experimental group (75 patients) and the control group (51 patients). Subjects and Methods: We used four main acupoints in our study – EX-B3, ST36, GB39, and GB34. We compared the changes of DPN symptoms, days of pain loss, changes of tendon reflexes, and electromyographic (EMG) parameters between two groups after 15 days of treatment. Statistical Analysis Used: T-test was used to compare the characteristics between different treatments. Results: The best acupoint set for performing the acupoint injection therapy with 5% Vitamin B1, includes EX-B3, ST36, GB34, and GB39. The mean efficiency rate in terms of changes of DPN symptoms was 84.5% that is significantly lower compared with 61.9% of control group. Furthermore, the day of the pain loss of experimental group was significant lower than that of control group and the efficiency rates in terms of patellar reflex and Achilles tendon reflex were 90.0% and 89.1%, respectively (P < 0.05). In the experimental group, EMG parameters were improved significantly. Conclusions: Our study suggests that the acupoint injection therapy with Vitamin B1is preferable, easier, and cost-effective approach in terms of DPN treatment.

Keywords

Acupoints - diabetic peripheral neuropathy - Vitamin B1

Financial support and sponsorship

Nil.




Publication History

Received: 24 July 2018

Accepted: 08 February 2019

Article published online:
08 June 2022

© 2019. Gulf Association of Endocrinology and Diabetes (GAED). All rights reserved. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004;27:1458-86.
  • 2 Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. Diabetic neuropathies: A statement by the American Diabetes Association. Diabetes Care 2005;28:956-62.
  • 3 Bennett M. The LANSS pain scale: The Leeds assessment of neuropathic symptoms and signs. Pain 2001;92:147-57.
  • 4 Backonja MM, Krause SJ. Neuropathic pain questionnaire – Short form. Clin J Pain 2003;19:315-6.
  • 5 Boulton A. Management of diabetic peripheral neuropathy. Clin Diabetes 2005;23:9-15.
  • 6 Lindsay TJ, Rodgers BC, Savath V, Hettinger K. Treating diabetic peripheral neuropathic pain. Am Fam Physician 2010;82:151-8.
  • 7 William T, George B, Lawrence B, Andrew B, David D, Mary DG, et al. Microvascular complications and foot care. Diabetes Care 2017;40 Suppl 1:S88-98.
  • 8 Waldschmitt C, Vogel F, Pfuhlmann B, Hiemke C. Duloxetine serum concentrations and clinical effects. Data from a therapeutic drug monitoring (TDM) survey. Pharmacopsychiatry 2009;42:189-93.
  • 9 Boulton AJ. Is duloxetine more effective than amitriptyline for painful diabetic neuropathy? Curr Diab Rep 2011;11:230.
  • 10 Smith HS, Argoff CE. Pharmacological treatment of diabetic neuropathic pain. Drugs 2011;71:557-89.
  • 11 Finnerup NB, Jensen TS. Clinical use of pregabalin in the management of central neuropathic pain. Neuropsychiatr Dis Treat 2007;3:885-91.
  • 12 Boyle J, Eriksson ME, Gribble L, Gouni R, Johnsen S, Coppini DV, et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: Impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care 2012;35:2451-8.
  • 13 Gubler CJ. Thiamin. In: Machlin LJ, editors. Handbook of Vitamins: Nutritional, Biochemical, and Clinical Aspects. New York, USA: Marcel Dekker; 1984. p. 245.
  • 14 Abuaisha BB, Costanzi JB, Boulton AJ. Acupuncture for the treatment of chronic painful peripheral diabetic neuropathy: A long-term study. Diabetes Res Clin Pract 1998;39:115-21.
  • 15 Guo CE. Peripheral diabetic neuropathy treated by integrative medicine. J Sichuan Tradit Chin Med 2001;19:39.
  • 16 Xin L, Tong WX, Zhang RF. Auxiliary therapy of Xuesaitong injection for DPN: A report of 31 patients. Chin J Integr Tradit West Med 2003;23:230.